PROBIOTICS IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASES IN CHILDREN
- Authors: A Kornienko Y.1, Lomakina Y.A1, Zaletova NK1, Fadina SA1, Kornienko E.A.1, Lomakina E.A.1, Zaletova N.K.1, Fadina S.A.1
-
Affiliations:
- Issue: No 15 (2010)
- Pages: 109-113
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/278626
- ID: 278626
Cite item
Full Text
Abstract
About the authors
Ye A Kornienko
Ye A Lomakina
N K Zaletova
S A Fadina
Elena Aleksandrovna Kornienko
Ekaterina Aleksandrovna Lomakina
Nadezhda Konstantinovna Zaletova
Svetlana Alekseevna Fadina
References
- Swidsinski A, Ladhoff A, Pemthaler A, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology 2002;122:44-54.
- Kuhn R, Lohler J, Rennick D, et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993;75:263-74.
- Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a doubleblind, placebo-controlled trial. Gastroenterology 2000; 119:305-309.
- Mimura T, Rizzello F, Helwig U, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004;53:108-14.
- Kuisma J, Mentula S, Jarvinen H, et al. Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora.Aliment Pharmacol Ther 2003;17:509-15.
- Laake KO, Line PD, Aabakken L, et al. Assessment of mucosal inflammation and circulation in response to probiotics in patients operated with ileal pouch anal anastomosis for ulcerative colitis. Scand J Gastroenterol 2003;38:409-14.
- Gionchetti P, Rizzello F, Helwig U, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003;124:1202-09.
- Bibiloni R, Fedorak RN, Tannock GW, et al. VSL#3 probioticmixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 2005;100:1539-46.
- Rembacken BJ, Snelling AM, Hawkey PM, et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 999;354:635-39.
- Rioux KP, Fedorak RN. Probiotics in the treatment of inflammatory bowel disease. J Clin Gastroenterol 2006;40:260-63.
- Guslandi M, Giollo P, Testoni PA. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 2003;15:697-98.
- Kruis W, Schutz E, Fric P, et al. Double-blind comparison of an oral Escherichia coli reparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997;11:853-58.
- Kruis W, Fric P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004;53:1617-23.
- Ishikawa H, Akedo I, Umesaki Y, et al. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J Am Coll Nutr 2003;22:56-63.
- Venturi A, Gionchetti P, Rizzello F, et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis.Aliment Pharmacol Ther 1999;13:1103-08.
- Gupta P, Andrew H, Kirschner BS, et al. Is Lactobacillus GG helpful in children with Crohn's disease? Results of preliminary, open-label study. J Pediatr Gastroenterol Nutr 2000; 31:453-57.
- Schultz M, Timmer A, Herfarth HH, et al. Lactobacillus GG in inducing and maintaining remission of Crohn's disease. BMC Gasroenterol 2004;4:5.
- Bousvaros A, Guandalini S, Baldassano RN, et al. A ranomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. Inflamm Bowel Dis 2005;11:833-39.
- Prantera C, Scribano ML, Falasco G, et al. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut 2002;51:405-09.
- Plein K, Hotz J. Therapeutic effects of Saccharamyces boulardii on mild residual symptoms in stable phase of Crohn's disease with special respect to chronic diarrhea - a pilot study. J Gasroenterol 1993;31:129-34.
- Guslandi M, Mezzi G, Sorghi M, et al. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 2000;45:1462-64.
- Czerucka D, Dahan S, Mograbi B, et al. Saccharomyces boulardii preserves the barrier function and modulates the signal transduction pathway induced in enteropathogenic Escherichia coli-infected T84 cells. Infect Immun 2000; 68:5998-6004.
- Dahan S, Dalmasso G, Imbert V, et al. Saccharomyces boulardii interferes with enterohemorragic Escherichia coli-induced signaling pathways in T84 cells. Infect Immun 2003;71:766-73.
- Czerucka D, Dahan S, Mograbi B, et al. Implication of mitogen-activated protein kinases in T84 cell responses to enteropathogenic Escherichia coli infection. Infect Immun 2001;69:1298-1305.
- Resta-Lenert S, Barrett KE. Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC). Gut 2003;52:988-97.
- Ruemmelle FM, Bier D, Marteau P, et al. Clinical evidence of immunomodulatory effects of probiotic bacteria. J Pediatr Gastroenterol Nutr 2009; 48(2):126-41.
- Foligne B, Zoumpopoulou G, Dewulf J, et al. A key role of dendritic cells in probiotic functionality. PLoS ONE 2007;2:313.